Rituxan goes off-patent in most of the big European countries in 2013 and in the US in 2015 (#msg-37325602). Generic versions of the drug in Europe from multiple vendors will likely hit the market soon after patent expiration; however, these generics will not be automatically substitutable for branded Rituxan/MabThera, and hence they will have to be actively marketed to gain a commercial foothold.
In the US, the prospects for substitutable and non-substitutable Rituxan generics depend on what Congress does with FoB legislation.
Market Data 
Markets 
AI
